KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Major Shareholder Venrock Healthcare Capital Par Acquires 4,137 Shares

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) major shareholder Venrock Healthcare Capital Par bought 4,137 shares of the company’s stock in a transaction dated Monday, February 10th. The stock was bought at an average cost of $9.14 per share, for a total transaction of $37,812.18. Following the acquisition, the insider now owns 5,090,582 shares of the company’s stock, valued at approximately $46,527,919.48. This trade represents a 0.08 % increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Major shareholders that own 10% or more of a company’s shares are required to disclose their sales and purchases with the SEC.

Venrock Healthcare Capital Par also recently made the following trade(s):

• On Friday, February 7th, Venrock Healthcare Capital Par acquired 73,649 shares of KalVista Pharmaceuticals stock. The stock was purchased at an average price of $9.29 per share, for a total transaction of $684,199.21.
• On Monday, February 3rd, Venrock Healthcare Capital Par acquired 14,562 shares of KalVista Pharmaceuticals stock. The shares were purchased at an average price of $9.22 per share, with a total value of $134,261.64.
• On Thursday, January 30th, Venrock Healthcare Capital Par bought 43,707 shares of KalVista Pharmaceuticals stock. The stock was purchased at an average cost of $8.76 per share, for a total transaction of $382,873.32.

KalVista Pharmaceuticals Stock Performance

KALV opened at $9.27 on Wednesday. The company has a market cap of $458.12 million, a price-to-earnings ratio of -2.55 and a beta of 0.85. KalVista Pharmaceuticals, Inc. has a one year low of $7.30 and a one year high of $16.88. The business’s fifty day moving average is $8.75 and its two-hundred day moving average is $10.58.

KalVista Pharmaceuticals (NASDAQ:KALV) last issued its quarterly earnings data on Thursday, December 5th. The specialty pharmaceutical company reported ($0.91) EPS for the quarter, beating analysts’ consensus estimates of ($0.92) by $0.01. On average, analysts predict that KalVista Pharmaceuticals, Inc. will post -3.56 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. Vestal Point Capital LP grew its holdings in KalVista Pharmaceuticals by 73.9% during the 3rd quarter. Vestal Point Capital LP now owns 4,000,000 shares of the specialty pharmaceutical company’s stock valued at $46,320,000 after buying an additional 1,700,000 shares during the last quarter. State Street Corp boosted its stake in shares of KalVista Pharmaceuticals by 68.1% during the third quarter. State Street Corp now owns 1,271,609 shares of the specialty pharmaceutical company’s stock valued at $14,725,000 after acquiring an additional 515,179 shares during the last quarter. Emerald Advisers LLC increased its position in KalVista Pharmaceuticals by 29.8% during the 3rd quarter. Emerald Advisers LLC now owns 835,988 shares of the specialty pharmaceutical company’s stock worth $9,681,000 after purchasing an additional 192,091 shares in the last quarter. Readystate Asset Management LP acquired a new position in KalVista Pharmaceuticals in the 3rd quarter valued at about $2,084,000. Finally, Emerald Mutual Fund Advisers Trust lifted its holdings in KalVista Pharmaceuticals by 23.0% in the 3rd quarter. Emerald Mutual Fund Advisers Trust now owns 650,980 shares of the specialty pharmaceutical company’s stock valued at $7,538,000 after purchasing an additional 121,615 shares in the last quarter.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on KALV. HC Wainwright restated a “buy” rating and issued a $20.00 price objective on shares of KalVista Pharmaceuticals in a research report on Friday, December 6th. TD Cowen assumed coverage on KalVista Pharmaceuticals in a report on Tuesday, January 7th. They issued a “buy” rating and a $30.00 price target for the company. JMP Securities began coverage on KalVista Pharmaceuticals in a report on Friday, January 31st. They set an “outperform” rating and a $19.00 price objective on the stock. Needham & Company LLC restated a “buy” rating and set a $28.00 target price on shares of KalVista Pharmaceuticals in a research report on Thursday, December 5th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of KalVista Pharmaceuticals in a research note on Monday, December 9th. Six investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of $23.80.

KalVista Pharmaceuticals Company Profile

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company’s product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).